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Abstract: BACKGROUND Intracranial artery dissection is an uncommon cause of acute ischemic stroke.
Although acute stenting of the dissected arterial segment is a therapeutic option, the associated an-
tiplatelet regimen remains a matter of debate. OBJECTIVES To evaluate the efficacy and safety of
acute intracranial stenting together with concomitant intravenous administration of tirofiban and to per-
form a systematic review of the literature. MATERIALS AND METHODS A single-center, retrospective
study of the clinical and radiological records of all patients treated at our center by intracranial stenting
in the setting of acute ischemic stroke between January 2010 and December 2020. A systematic review
of the literature was conducted according to the PRISMA-P guidelines for relevant publications from
January 1976 to December 2020 on intracranial artery dissection treated by stent. RESULTS Seven
patients with intracranial artery dissections underwent acute stenting with concomitant tirofiban during
the study period. Mid-term follow-up showed parent artery patency in 6/7 cases (85.7%). The modified
Rankin Score was ฀ 0-2 at 3 months in 5/7 cases (71.4%). The literature review identified 22 patients
with intracranial artery dissection treated with acute stenting in association with different antithrombotic
therapies. Complete revascularization was obtained in 86.3% of cases with a modified Rankin Score of ฀
0-2 in 68% of patients at 3-month follow-up. CONCLUSIONS Acute intracranial stenting together with
intravenous tirofiban administration could be a therapeutic option in patients with intracranial artery
dissection and a small ischemic core.
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Background: Intracranial artery dissection is an uncommon cause of acute ischemic
stroke. Although acute stenting of the dissected arterial segment is a therapeutic
option, the associated antiplatelet regimen remains a matter of debate. Objectives: To
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tant intravenous administration of tirofiban and to perform a systematic review of
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fied 22 patients with intracranial artery dissection treated with acute stenting in asso-
ciation with different antithrombotic therapies. Complete revascularization was
obtained in 86.3% of cases with a modified Rankin Score of  0-2 in 68% of patients
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nous tirofiban administration could be a therapeutic option in patients with intracra-
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Introduction
Intracranial artery dissection (IAD) is an uncommon
cause of acute ischemic stroke (AIS) often leading to flow-
limiting stenosis.14 Irrespective of whether an IAD is rec-
ognized or not, stent retriever (SR) thrombectomy and
direct thrombus aspiration are considered as first-line tech-
niques. However, such endovascular treatments could
result in a less effective and stable revascularization5 and
stenting of the artery has been reported as an effective
treatment for reestablishing the patency of the dissected
segment.1,59 Nevertheless, the optimal medical manage-
ment associated with acute stenting is not well-established.
A loading dose of clopidogrel and aspirin is most com-
monly administered to patients before stent implantation,
taking into consideration the time lapse for drug activation.
The use of intravenous tirofiban or abiciximab is consid-
ered when a prompt antiplatelet effect is required,
although their clinical use is off-label for AIS treatment
because of the potential increment of bleeding risk.
In this study, we report our experience in treating AIS
patients presenting with an IAD by acute stenting per-
formed in association with intravenous administration of
tirofiban. We aimed to evaluate the efficacy and the safety
of such an approach in the per-operative period and mid-
term follow-up. A comprehensive systematic review of
the literature was also conducted in order to obtain data
regarding the efficacy and safety of intracranial stenting,
together with the associated antiplatelet strategy in
patients with AIS related to IAD.
Material and methods
Patient population
This is a single-center, retrospective review of the clini-
cal and radiological records of all AIS patients treated at
our institution by acute intracranial stenting between Jan-
uary 2010 and December 2020. All patients who received
this treatment for a suspected IAD, with the concomitant
administration of intravenous tirofiban, were included in
the study. The study was approved by the local institu-
tional review board.
Periprocedural digital subtraction angiographies were
retrospectively reviewed by two physicians with experi-
ence in intracranial stenting (PM, GB) in a consensus read-
ing in order to assess the presence of an IAD as the cause
of the AIS, according to specific radiological criteria previ-
ously reported by Labeyrie et al.5 (Table S1). The reviewers
also analyzed the immediate follow-up images (CT, MRI)
to identify the presence of complications and patency of
the stented artery. Finally, patients’ clinical records were
reviewed to evaluate their mid-term clinical outcome.
Patient selection
According to our institutional protocol, patients
presenting with AIS were evaluated by CT scan,
CT-perfusion and CT-angiography. Patients referred from
peripheral hospitals were directly admitted to the angiog-
raphy suite. The volume of the ischemic core and penum-
bra of the former group was calculated using an
automated software (RAPID software, iSchemiaView,
Redwood City, CA), while the ABC/2 method10 was used
to calculate the ischemic core extent according to diffu-
sion-weighted imaging (DWI) for those referred from
peripheral hospitals and selected by MRI. Patients with
stroke onset within 8 hours were considered eligible for
endovascular treatment, irrespective of the ischemic core
extent. For patients admitted more than 8 hours after
stroke onset, a cerebral blood flow reduction of 70mL
and a cerebral blood flow/Tmax mismatch ratio of 1.8
were considered as inclusion criteria for endovascular
treatment within 24 hours of symptom onset. Large vessel
occlusion in the posterior circulation was considered as
eligible for endovascular treatment within 24 hours from
symptom onset. Eligible patients received intravenous rt-
PA prior to the procedure.
Prediction criteria for IAD
Clinical criteria for a suspicion of IAD were based on
patients' young age and the presence of intense headache
at the onset of neurological deficits. Radiological criteria
for suspecting IAD on the admitting examination (CT/
CTA, MRA/MRI) were the focal stenosis or occlusion of
the artery, mural hematoma or intimal flap. The following
procedural findings were taken into account to establish
the diagnosis of IAD at the time of endovascular treat-
ment: obtention of a bypass effect upon stent retrieval,
and arterial re-occlusion after stent retriever removal/
resheathing.
Endovascular technique
Patients suspected for IAD were treated according to the
following algorithm. Endovascular procedures were per-
formed with patients under general anesthesia using a bi-
plane C-arm (Allura Clarity FD20, Philips Healthcare, Best,
The Netherlands) via a common femoral artery approach.
According to our institutional protocol, the procedures were
performed without heparinization. A large-bore aspiration
catheter was advanced over a microcatheter (Headway 0.21;
MicroVention, Aliso Viejo, California, USA) at the proximal
margin of the dissection and negative pressure was applied
to perform a direct thrombus aspiration. A stent retriever
(SR) (Solitaire FR, Medtronic, Dublin, Ireland; TREVO
Striker, Kalamazoo, MI, USA) was unsheathed across the
dissection in order to obtain a bypass effect.
If the normalization of the arterial caliber was achieved,
the SR was re-sheathed, while the delivery microcatheter
was advanced during the re-sheathing beyond the dis-
sected segment, with an intravenous bolus of tirofiban (10
mg/kg) administered over a period of 3 minutes, according
to the patient’s body weight.11 Finally, after 5-10
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minutes,11,12 a self-expanding intracranial stent with a com-
plete section (Enterprise, Codman Neurovascular, Rayn-
ham, MA, USA) was deployed via the same microcatheter
across the dissected arterial segment. When required, due
to the extent of the dissection, a second stent (Neuroform
Atlas Stryker, Kalamazoo, MI, USA; Solitaire AB) was
deployed to completely cover the dissected segment.
Immediately after the intravenous bolus, an intravenous
infusion of tirofiban (0.1 mg/kg/min) was maintained for
up to 24 hours. After a CT-angiography or MRI performed
to confirm stent patency and to exclude intracranial hemor-
rhage, a loading dose of 300 mg of clopidogrel was admin-
istered 6 hours before the end of the tirofiban infusion.
Patients were monitored in the intensive care unit during
the 24-hour postoperative period. At 48 hours, 75 mg of
clopidogrel associated with 100 mg of aspirin were admin-
istered to the patients as a long-term therapy (6 months),
followed by indefinite therapy with aspirin. Mid-term
patency (between 3 and 6 months after the procedure) of
the stent was evaluated by CT-angiography, magnetic res-
onance angiography or transcranial Doppler.
Patient outcome criteria
Clinical and radiological outcomes of patients were
assessed according to the following criteria: patency of
the stented artery, together with the occurrence of ICH at
the immediate and mid-term follow-up (3-6 months); shift
of the NIHSS at 24 hours after the procedure; and clinical
outcome at day 90 according to the modified Rankin Score
(mRS) scale.
Literature review
Data sources and searches
Three online databases (Embase, PubMed and the
Cochrane library) were searched for articles published
between January 1976 and December 2020 on IAD treated
by stent according to the PRISMA-P guidelines (Table S2).
Medical subject headings and keyword searches included
the terms ((stroke) AND (intracranial artery dissection))
NOT (aneurysm). In addition, the reference lists of
selected articles and pertinent available non-systematic
analyses were reviewed for other potential citations. Data
from unpublished sources were not searched or included.
Study selection and data extraction
Two investigators (GB and PM) conducted independent
literature searches and data extraction using a standard-
ized approach. Based on title and abstract screening,
selected publications were initially reviewed by the same
investigators to assess if the studies met the inclusion cri-
teria, i.e. studies describing patients with AIS due to an
IAD treated by intracranial stenting in the acute phase.
Exclusion criteria were studies concerning extracranial
isolated dissection, conservative management without
endovascular treatment, case reports and nonEnglish
language publications, congress abstracts, letters to the
editor, and atherosclerotic intracranial stenosis. Studies
describing extracranial arterial dissection, medical or
diagnostic management of an IAD were also excluded
after full text assessment. Any disagreement was resolved
by a third author (Fig. 1). The following data were
extracted: number of patients; patient characteristics;
intervention characteristics; complications; symptomatic
intracranial hemorrhages; functional outcomes; and mor-
tality. Bias risk assessment was assessed by the Cochrane
Collaboration’s Risk of Bias Tool.13
Study outcomes
IAD reperfusion after stenting was evaluated overall in
the included studies and the clinical outcome was graded
according to the mRS at 3 months, with a mRS  2 consid-
ered as a favorable outcome.
Statistical analysis
Descriptive statistics were performed. Patient characteris-
tics and discrete variables were presented as mean +/- stan-
dard deviation (SD). Continuous variables were presented
as mean +/- SD or as the median, 25th and 75th percentile.
Results
Case series
A total of 64 patients presenting with an AIS due to
large-vessel occlusion were treated at our center by intra-
cranial stenting during the study period. Among these,
we identified 7 patients with AIS related to an IAD treated
by acute stenting and concomitant administration of tiro-
fiban. Moreover, thirteen additional patients presenting
with an intracranial dissection associated with an intracra-
nial hemorrhage were admitted at our center during the
study period. Given the different clinical and therapeutic
implications of such condition, this group of patients was
not considered for the aim of the present study.
Patient characteristics are shown in Table 1 (mean age
37.4 [standard deviation (SD) 13.2]; 4 [57.1%] were
female).
Mean ischemic core volume was 6.75 ml (range 0-31 ml)
in 6 patients and the mean onset to groin was 219 minutes
(SD 106 minutes). Dissected arteries were the M1 segment
of the middle cerebral artery (n=2/7), supraclinoid seg-
ment of the internal carotid artery (n=3/7), internal
carotid terminus (n=1/7), and V3 segment of the vertebral
artery, extending to the proximal and middle-third of the
basilar artery (n=1/7). In 5/7 cases (71.4%), intravenous
rt-PA was administered.
The direct thrombus aspiration used as the first-line
approach (n=5/7) was ineffective in establishing recanali-
zation in all cases. A SR was subsequently deployed
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within the dissected portion of the artery in order to verify
if the artery regained a normal lumen upon stent deploy-
ment. In each case, the “bypass effect” achieved by the SR
confirmed the suspicion of an IAD. Consequently, the SR
was re-sheathed into a delivery microcatheter without
any SR thrombectomy attempt in 5/7 cases. The delivery
microcatheter was advanced during the re-sheathing
beyond the dissected segment and used to implant a stent
covering the complete IAD section (Fig. 2).
An Enterprise stent was used as a permanent stent in all
cases (n=7/7). In 2 cases, a second stent was added (Soli-
taire AB [n=1/7]; Neuroform Atlas [n=1/7]). An intrave-
nous bolus of tirofiban (10 mg/kg) was administered to
all patients in a 3-minute time lapse according to body
Fig. 1. PRISMA-P flow diagram.
Table 1. Patients’ baseline characteristics, per-operative data and clinical evolution.
PT. 1 PT.2 PT.3 PT.4 PT.5 PT.6 PT.7
Gender F M M F F F M
Age (years) 30-39 10-19 30-39 50-59 30-39 20-29 50-59
IAD location M1 left ICA left M1 right V-B ICA left ICA right ICA T left
Mural hematoma yes yes yes yes yes yes yes
Arterial stenosis/occlusion yes yes yes yes yes yes yes
Intimal flap yes yes yes yes yes yes no
Artery normalization yes yes yes yes yes yes yes
Ischemic core 3 ml 1 ml 0 ml - 31 ml 5.5 ml 0
Ischemic penumbra 102 ml - 126 ml - 109 ml 117ml 62 ml
rtPA i.v. yes yes no no yes yes yes
Onset to groin 135 min. 245 min. 235 min. 380 min. 320 min. 110 min. 110 min.
Tirofiban yes yes yes yes yes yes yes
Stent patency yes yes yes yes yes yes no
NIHSS admission 18 17 8 15 15 15 4
NIHSS discharge 2 2 4 2 4 0 24
Hemorrhagic complications no no no no no no no
Mid-term stroke recurrence no no no no no no no
mRS at 3 months 2 0 1 2 3 1 5
Stent patency at follow-up yes yes yes yes yes yes no
IAD, intracranial artery dissection; i.v., intravenous; V-B, vertebra-basilar; T, terminus.
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weight and the stent was deployed 5-10 minutes after this
bolus.11,12 An intravenous infusion (0.1mg/kg/min) of tir-
ofiban was also administered at the same time and main-
tained for up to 24 hours. In 6/7 cases, the stent was
patent after delivery. In the remaining case, the stent
occluded a few minutes after the initial post-deployment
control had showed patency of the device. This patient
developed a large ischemic lesion of the related brain
parenchyma and had a poor clinical outcome at the mid-
term follow-up. There were no cases of hemorrhagic com-
plications.
In 6/7 cases, the neurological evaluation at 24 hours
from onset showed an important clinical improvement
associated with a substantial decrease of the NIHSS at dis-
charge (mean 5.43 points [SD 8.30]) compared to the
admission NIHSS (mean 13.14 points [SD 5.14]) (Table 1).
No patients had ischemic stroke recurrence in the follow-
up period. The mRS at 3-months’ follow-up was 0-2 in 5/
7 patients (71.4%), while one patient presented a mRS 3,
and one a mRS 5. At mid-term follow-up, 6/7 involved




The initial database search yielded 333 articles. After
removal of duplicates, 318 studies remained. Thirty-one
non-English language articles were then removed and the
remaining studies were screened by analyzing the title
and abstract. Twenty-eight full text articles were assessed
for eligibility. At the end of the process, four studies with
a total of 22 patients were included in the qualitative syn-
thesis. The results of our literature screening are summa-
rized in Table 2.
All included publications were retrospective case series.
Hence, an overall high risk of bias was associated with
the included studies (Table S3). Only two domains pre-
sented a low risk of bias, namely, outcome measurements
and selection of the reported results (Table S3).
Procedural data and IAD treatment
In the included studies, all IAD were managed by endo-
vascular treatment, i.e. intracranial stenting. Two series
used tirofiban as an antithrombotic drug,8,14 while a com-
bination of aspirin and clopidogrel was used in 3/4
studies.5,7,14 In one series, abiciximab was also used.5
Reperfusion data and clinical outcome
Reperfusion data were reported in all studies. A com-
plete reperfusion was achieved in 19/22 patients (86.3%).
Clinical outcome was generally assessed using the mRS at
3 months. In 15/22 patients (68%), mRS was  2 at fol-
low-up.
Discussion
Our systematic literature review showed that intracra-
nial stenting in patients with AIS due to an IAD (Table 2)
could be considered a valuable therapeutic option for
selected patients. In particular, a complete recanalization
was achieved in in 86.3% of cases, resulting in a good clin-
ical outcome (mRS 2) in 68% of cases at 3 months’ fol-
low-up. The results of our clinical study are in line with
those of the systematic literature review with respect to
the efficacy and safety of acute intracranial stenting and
also suggest a potential use for a concomitant intravenous
administration of tirofiban for IAD treatment. In our
series, such management was effective in 6/7 cases
(85.7%) and a complete artery revascularization was
achieved without significant residual intra-stent stenosis
at midterm follow-up, with a 3-months’ mRS  2 in 5/7
patients (71.4%). Conservative management with rt-PA
and/or antiplatelets or anticoagulants has been described
as an effective treatment for IAD, especially in the case of
mild neurological deficits.15,16 Although endovascular
treatment can be considered for selected patients with
large vessel occlusions, being stent reconstruction is a rea-
sonable option.16
IADs that present with ischemic symptoms have a
lower risk of intracerebral hemorrhage compared to those
with subarachnoid hemorrhage.5,17 However, as widely
Fig. 2. Dissection of the supraclinoid segment of the right internal carotid artery. A) initial occlusion; B) image performed with unsheathed stent retriever;
C) result after stent retrieval; D) result after final stent implantation and intravenous bolus of tirofiban.
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reported, any anti-thrombotic therapy administered to
patients with AIS increases the risk of intracerebral hem-
orrhage.1820 The efficacy and safety of tirofiban has
already been evaluated for intracranial aneurysms,2124
as well as for AIS.14,2527 Nevertheless, in patients with
AIS, the size of the ischemic core and the time of onset
have to be considered before any administration of anti-
platelet therapy to assess the risk of hemorrhage. To our
knowledge, the present study represents the largest series
of IAD treated by acute stenting and intravenous tirofi-
ban. Importantly, there were no cases of hemorrhagic
complications.
In the studies included in our systematic literature
review, aspirin and clopidogrel were used as antithrom-
botic therapy for intracranial stent implantation in 3/4
studies. Tirofiban was administered in 6/22 cases, but
resulted in a good clinical outcome in only 50% of
patients. Forbrig et al.14 treated IADs with acute stenting
and used tirofiban in 3/4 cases as rescue treatment after
SR thrombectomy. They obtained a low reperfusion rate
after stent implantation, with relatively poor patient out-
comes as no patient had an mRS 2 at 3 months and 2/4
patients suffered a symptomatic intracerebral hemor-
rhage.14 By contrast, Jeon et al.8 performed intracranial
stenting together with tirofiban as first-line treatment for
IAD in three cases without any attempt of SR thrombec-
tomy and reported obtaining a complete reperfusion asso-
ciated with good clinical outcome (mRS 2 at 3 months)
in most cases, without any symptomatic intracerebral
hemorrhage.
Therefore, it could be argued that the differences in
terms of procedure success and outcome of the two stud-
ies were related to the absence of thrombectomy maneu-
vers in the study in which artery stenting was considered
as first-line treatment, given that STR passes are poten-
tially associated with the further dissection and damage
of the target vessel. IAD is frequently under-recognized
during the acute phase of ischemic stroke3 and intracra-
nial stenting is frequently considered as a rescue
technique5,14,25,26,28 for patients in whom first-line throm-
bectomy strategies do not result in a stable revasculariza-
tion. In our opinion, early identification of an IAD is
crucial for the success of the stenting procedure.
SR thrombectomy may lead to endothelial damage29
that may interfere with stent deployment in the case of
stroke-related IADs, regardless of the antiplatelet regi-
men. In our series, an IAD was suspected before the pro-
cedure in all patients according to the patient’s associated
risk factors and radiological criteria, such as the admitting
CT/CT-angiography or MRI/MRI-angiography, together
with initial DSA imaging, according to the criteria already
mentioned previously. No SR thrombectomy was per-
formed before stent deployment and tirofiban administra-
tion in 5/7 cases, allowing to obtain a complete
revascularization in 6/7 cases. All patients presented a
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hemorrhagic complication occurred despite the associa-
tion between rt-PA and tirofiban, also in the case of stent
occlusion that leads to a large infarct volume.
Only small clinical series or case reports have described
the efficacy of acute stenting for IAD.1,59,14 Labeyrie et al.5
reported 13 cases of IAD treated with medical therapy,
mechanical thrombectomy or acute stenting. In their study,
stenting of the target artery was performed in 7/13 cases
and was significantly associated with a lower rate of resid-
ual dissection-related stenosis compared with SR throm-
bectomy or medical therapy. Moreover, IADs treated with
stent deployment had a lower ischemic recurrence com-
pared with the other treatments. In another study, Kim
et al.7 reported eight IADs treated with stenting, achieving
a 3-month mRS of 0-2 in all patients. In this study, all stents
were patent without significant residual intra-stent stenosis
at angiographic follow-up. In both of the above-mentioned
studies,5,7 most patients had longer onset-to-groin-times
compared to our study population as they had neurologi-
cal symptoms at admission related to crescendo strokes,
and most received premedication with a loading-dose of
dual antiplatelet drugs before stent implantation. In our
study, all patients presented with severe neurological defi-
cits at admission. Consequently, the onset-to-groin-times
was short compared to previous studies. An intravenous
bolus of tirofiban was administered to all patients 5 to 10
minutes before stent implantation, followed by a mainte-
nance infusion over the next 24 hours. This treatment pro-
tocol was established to secure a rapid and effective
antiplatelet therapy prior to stent implantation, knowing
that the complete antithrombotic effect of clopidogrel
(loading dose of 600 mg) is achieved only between 2 and
4 hours after its administration.30
As previously reported by Woo et al.26 the intravenous
administration of tirofiban concomitant with stent deploy-
ment was related to a significantly lower rate of acute in-
stent thrombosis, as well as a better clinical outcome com-
pared to patients who did not receive tirofiban. This find-
ing was confirmed by our experience. In 6/7 cases, the
stents were patent at mid-term follow-up and without
signs of intra-stent stenosis. In addition, none of these 6
patients presented a recurrence of ischemic stroke during
the follow-up period. A novel alternative pharmacological
option that is gaining consensus among neurointerven-
tionalists is the use of intravenous P2Y12 receptor antago-
nists both for patients with AIS and those with
hemorrhagic stroke who need prompt antiplatelet
therapy.3134 Nevertheless, reports and evidence for such
drug use in cases of IAD are lacking.
Study limitations
Our study has several limitations related to its retro-
spective design, single-center setting and the small num-
ber of patients. In addition, tirofiban is not available in all
countries, thus limiting the generalization of the results.
However, it should be noted that the rarity of IAD pub-
lished reports has so far precluded a definition of a stan-
dard of care for such a disease and further research is
needed.
Conclusions
Our study suggests that intracranial stenting of IAD
with concomitant tirofiban administration in the acute
phase is an effective and safe endovascular treatment in
patients with a small ischemic core.
Funding
This work was supported by the Swiss National Science
Foundation (grant nos. 320030_188942 and 32003B_182382).
The funder had no role in study design, data collection and
analysis, decision to publish, or preparation of the manu-
script.
Competing interests
PM is consultant for Medtronic and Stryker. All other
authors declare no competing interests.
Contributors
Substantial contributions to the conception or design of
the work; or the acquisition, analysis, or interpretation of
data for the work; drafting the work; revising it critically
for important intellectual content; final approval of the
version to be published; and agreement to be accountable
for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work
are appropriately investigated and resolved: all authors.
Data sharing statement
All the data are available upon request to the corre-
sponding author.
Patient consent for publication
Not required.
Ethics approval
Ethics approval was obtained from the local institu-
tional review board.
Supplementary materials
Supplementary material associated with this article can
be found in the online version at doi:10.1016/j.jstrokecere
brovasdis.2021.105891.
References
1. Binning MJ, Khalessi AA, Siddiqui AH, et al. Stent place-
ment for the treatment of a symptomatic intracranial arterial
ACUTE STENTING OF INTRACRANIAL ARTERY DISSECTIONS 7
dissection in an adolescent. J Neurosurg Pediatr 2010;6
(2):154-158. https://doi.org/10.3171/2010.4.Peds1081. [pub-
lished Online First: 2010/08/03].
2. Debette S, Compter A, Labeyrie MA, et al. Epidemiology,
pathophysiology, diagnosis, and management of intracra-
nial artery dissection. Lancet Neurol 2015;14(6):640-654.
https://doi.org/10.1016/s1474-4422(15)00009-5. [published
Online First: 2015/05/20].
3. Montalvan V, Ulrich A, Wahlster S, et al. Arterial dissec-
tion as a cause of intracranial stenosis: a narrative review.
Clin Neurol Neurosurg 2020;190:105653. https://doi.
org/10.1016/j.clineuro.2019.105653. [published Online
First: 2020/01/07].
4. Sikkema T, Uyttenboogaart M, Eshghi O, et al. Intracra-
nial artery dissection. Eur J Neurol 2014;21(6):820-826.
https://doi.org/10.1111/ene.12384. [published Online
First: 2014/05/16].
5. Labeyrie MA, Civelli V, Reiner P, et al. Prevalence and
treatment of spontaneous intracranial artery dissections
in patients with acute stroke due to intracranial large ves-
sel occlusion. J Neurointerv Surg 2018;10(8):761-764.
https://doi.org/10.1136/neurintsurg-2018-013763. [pub-
lished Online First: 2018/03/08].
6. Racchiusa S, Longo M, Bernava G, et al. Endovascular
treatment of spontaneous intracranial internal carotid
dissection in a young patient affected by systemic lupus
erythematosus: a case report. J Vasc Interv Neurol 2017;9
(5):1-7. [published Online First: 2017/11/23].
7. Kim DJ, Kim BM, Suh SH, et al. Self-expanding stent place-
ment for anterior circulation intracranial artery dissection
presenting with ischemic symptoms. Neurosurgery 2015;76
(2):158-164. https://doi.org/10.1227/neu.0000000000000582.
discussion 64[published Online First: 2014/12/31].
8. Jeon P, Kim BM, Kim DI, et al. Emergent self-expanding
stent placement for acute intracranial or extracranial
internal carotid artery dissection with significant hemo-
dynamic insufficiency. AJNR Am J Neuroradiol 2010;31
(8):1529-1532. https://doi.org/10.3174/ajnr.A2115. [pub-
lished Online First: 2010/05/01].
9. Biondi A, Katz JM, Vallabh J, et al. Progressive symp-
tomatic carotid dissection treated with multiple stents.
Stroke 2005;36(9):e80-e82. https://doi.org/10.1161/01.
STR.0000177883.50262.cf. [published Online First:
2005/08/16].
10. Sims JR, Gharai LR, Schaefer PW, et al. ABC/2 for rapid
clinical estimate of infarct, perfusion, and mismatch vol-
umes. Neurology 2009;72(24):2104-2110. https://doi.
org/10.1212/WNL.0b013e3181aa5329. [published Online
First: 2009/06/17].
11. Effects of platelet glycoprotein IIb/IIIa blockade with tir-
ofiban on adverse cardiac events in patients with unsta-
ble angina or acute myocardial infarction undergoing
coronary angioplasty. The RESTORE Investigators. Ran-
domized Efficacy Study of Tirofiban for Outcomes and
REstenosis. Circulation 1997;96(5):1445-1453. https://
doi.org/10.1161/01.cir.96.5.1445. [published Online First:
1997/10/07].
12. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care
measured platelet inhibition correlates with a reduced risk
of an adverse cardiac event after percutaneous coronary
intervention: results of the GOLD (AU-Assessing Ultegra)
multicenter study. Circulation 2001;103(21):2572-2578.
https://doi.org/10.1161/01.cir.103.21.2572. [published
Online First: 2001/05/31].
13. McGuinness LA, Higgins JPT. Risk-of-bias VISualization
(robvis): an R package and Shiny web app for visualizing
risk-of-bias assessments. Res Synth Methods 2020.
https://doi.org/10.1002/jrsm.1411. [published Online
First: 2020/04/27].
14. Forbrig R, Lockau H, Flottmann F, et al. Intracranial res-
cue stent angioplasty after stent-retriever thrombectomy:
multicenter experience. Clin Neuroradiol 2019;29(3):445-
457. https://doi.org/10.1007/s00062-018-0690-4. [pub-
lished Online First: 2018/05/16].
15. Metso TM, Metso AJ, Helenius J, et al. Prognosis and
safety of anticoagulation in intracranial artery dissections
in adults. Stroke 2007;38(6):1837-1842. https://doi.org/
10.1161/strokeaha.106.479501. [published Online First:
2007/05/15].
16. Bond KM, Krings T, Lanzino G, et al. Intracranial dissec-
tions: a pictorial review of pathophysiology, imaging fea-
tures, and natural history. J Neuroradiol 2020. https://
doi.org/10.1016/j.neurad.2020.03.007. [published Online
First: 2020/04/27].
17. Ono H, Nakatomi H, Tsutsumi K, et al. Symptomatic
recurrence of intracranial arterial dissections: follow-up
study of 143 consecutive cases and pathological investi-
gation. Stroke 2013;44(1):126-131. https://doi.org/
10.1161/strokeaha.112.670745. [published Online First:
2012/12/04].
18. Kappelhof M, Marquering HA, Berkhemer OA, et al.
Intra-arterial treatment of patients with acute ischemic
stroke and internal carotid artery occlusion: a literature
review. J Neurointerv Surg 2015;7(1):8-15. https://doi.
org/10.1136/neurintsurg-2013-011004. [published Online
First: 2014/01/05].
19. Eker OF, B€uhlmann M, Dargazanli C, et al. Endovascular
treatment of atherosclerotic tandem occlusions in anterior
circulation stroke: technical aspects and complications
compared to isolated intracranial occlusions. Front Neurol
2018;9:1046. https://doi.org/10.3389/fneur.2018.01046.
[published Online First: 2019/01/09].
20. Diener HC, Foerch C, Riess H, et al. Treatment of acute
ischaemic stroke with thrombolysis or thrombectomy in
patients receiving anti-thrombotic treatment. Lancet Neu-
rol 2013;12(7):677-688. https://doi.org/10.1016/s1474-
4422(13)70101-7. [published Online First: 2013/06/04].
21. Kim S, Choi JH, Kang M, et al. Safety and efficacy of
intravenous tirofiban as antiplatelet premedication for
stent-assisted coiling in acutely ruptured intracranial
aneurysms. AJNR Am J Neuroradiol 2016;37(3):508-514.
https://doi.org/10.3174/ajnr.A4551. [published Online
First: 2015/10/17].
22. Limaye K, Zanaty M, Hudson J, et al. The safety and effi-
cacy of continuous tirofiban as a monoantiplatelet ther-
apy in the management of ruptured aneurysms treated
using stent-assisted coiling or flow diversion and requir-
ing ventricular drainage. Neurosurgery 2019;85(6):E1037-
E1042. https://doi.org/10.1093/neuros/nyz226. [pub-
lished Online First: 2019/07/13].
23. Liang XD, Wang ZL, Li TX, et al. Safety and efficacy of a
new prophylactic tirofiban protocol without oral intrao-
perative antiplatelet therapy for endovascular treatment
of ruptured intracranial aneurysms. J Neurointerv Surg
2016;8(11):1148-1153. https://doi.org/10.1136/neurint-
surg-2015-012055. [published Online First: 2015/11/29].
24. Dornbos 3rd D, Katz JS, Youssef P, et al. Glycoprotein
IIb/IIIa inhibitors in prevention and rescue treatment of
thromboembolic complications during endovascular
embolization of intracranial aneurysms. Neurosurgery
2018;82(3):268-277. https://doi.org/10.1093/neuros/
nyx170. [published Online First: 2017/05/05].
8 G. BERNAVA ET AL.
25. Baek JH, Kim BM, Kim DJ, et al. Stenting as a rescue treat-
ment after failure of mechanical thrombectomy for anterior
circulation large artery occlusion. Stroke 2016;47(9):2360-
2363. https://doi.org/10.1161/strokeaha.116.014073. [pub-
lished Online First: 2016/07/23].
26. Woo HG, Sunwoo L, Jung C, et al. Feasibility of permanent
stenting with solitaire FR as a rescue treatment for the reper-
fusion of acute intracranial artery occlusion. AJNR Am J
Neuroradiol 2018;39(2):331-336. https://doi.org/10.3174/
ajnr.A5477. [published Online First: 2017/12/16].
27. Yang M, Huo X, Miao Z, et al. Platelet glycoprotein IIb/
IIIa receptor inhibitor tirofiban in acute ischemic stroke.
Drugs 2019;79(5):515-529. https://doi.org/10.1007/
s40265-019-01078-0. [published Online First: 2019/03/07].
28. Dobrocky T, Kaesmacher J, Bellwald S, et al. Stent-
retriever thrombectomy and rescue treatment of M1
occlusions due to underlying intracranial atherosclerotic
stenosis: cohort analysis and review of the literature. Car-
diovasc Intervent Radiol 2019;42(6):863-872. https://doi.
org/10.1007/s00270-019-02187-9. [published Online
First: 2019/03/13].
29. Gao F, Lo WT, Sun X, et al. Combined use of mechanical
thrombectomy with angioplasty and stenting for acute
basilar occlusions with underlying severe intracranial
vertebrobasilar stenosis: preliminary experience from a
single Chinese center. AJNR Am J Neuroradiol 2015;36
(10):1947-1952. https://doi.org/10.3174/ajnr.A4364.
[published Online First: 2015/06/20].
30. HochholzerW, Trenk D, Frundi D, et al. Time dependence of
platelet inhibition after a 600-mg loading dose of clopidogrel
in a large, unselected cohort of candidates for percutaneous
coronary intervention. Circulation 2005;111(20):2560-2564.
https://doi.org/10.1161/01.Cir.0000160869.75810.98. [pub-
lished Online First: 2005/04/06].
31. Linfante I, Ravipati K, Starosciak AK, et al. Intravenous
cangrelor and oral ticagrelor as an alternative to clopi-
dogrel in acute intervention. J Neurointerv Surg 2021;13
(1):30-32. https://doi.org/10.1136/neurintsurg-2020-
015841. [published Online First: 2020/05/18].
32. Aguilar-Salinas P, Agnoletto GJ, Brasiliense LBC, et al.
Safety and efficacy of cangrelor in acute stenting for the
treatment of cerebrovascular pathology: preliminary expe-
rience in a single-center pilot study. J Neurointerv Surg
2019;11(4):347-351. https://doi.org/10.1136/neurintsurg-
2018-014396. [published Online First: 2018/12/16].
33. Cervo A, Ferrari F, Barchetti G, et al. Use of cangrelor in
cervical and intracranial stenting for the treatment of
acute ischemic stroke: a "Real Life" single-center experi-
ence. AJNR Am J Neuroradiol 2020;41(11):2094-2099.
https://doi.org/10.3174/ajnr.A6785. [published Online
First: 2020/10/10].
34. Cortez GM, Monteiro A, Sourour N, et al. The use of
cangrelor in neurovascular interventions: a multicenter
experience. Neuroradiology 2020. https://doi.org/
10.1007/s00234-020-02599-2. [published Online First:
2020/11/12].
ACUTE STENTING OF INTRACRANIAL ARTERY DISSECTIONS 9
